Wave Life Sciences Ltd (WVE)

Currency in USD
2.825
-0.045(-1.57%)
Real-time Data·
Trading near 52-week Low
WVE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.7702.890
52 wk Range
2.77021.730
Key Statistics
Prev. Close
2.87
Open
2.81
Day's Range
2.77-2.89
52 wk Range
2.77-21.73
Volume
757.19K
Average Volume (3m)
3.15M
1-Year Change
-60.4895%
Book Value / Share
2.04
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
WVE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.632
Upside
+488.73%
Members' Sentiments
Bearish
Bullish
ProTips
7 analysts have revised their earnings upwards for the upcoming period

Wave Life Sciences Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

19 Buy
2 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 16.632
(+488.73% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citi
Buy15.00+428.91%19.00Maintain12/11/2026
Canaccord
Buy44.00+1,451.48%42.00Maintain29/10/2026
Oppenheimer
Buy29.00+922.57%32.00Maintain28/10/2026
William Blair
Buy---New Coverage16/10/2026
UBS
Buy11.00+287.87%-New Coverage14/10/2026

Wave Life Sciences Ltd SWOT Analysis


RNA Editing Pionee
Wave Life Sciences leads in RNA editing oligonucleotides, targeting genetic diseases with a diverse pipeline and promising early-stage results in key programs
AATD Breakthrough
Explore WVE-006's potential for monthly dosing in alpha-1 antitrypsin deficiency, with favorable regulatory pathways and encouraging safety data
Obesity Market Entry
Delve into Wave's unique INHBE-targeting approach for obesity treatment, offering potential yearly dosing and differentiation in a competitive landscape
Financial Outlook
Analyst price targets range from $9 to $36, with a consensus "Strong Buy" recommendation despite near-term profitability challenges
Read full SWOT analysis

Wave Life Sciences Ltd Earnings Call Summary for Q3/2026

  • Wave Life Sciences Q3 2026 revenue hit $13.2M, beating estimates by 82% on GSK collaboration income; EPS of -$0.30 also topped forecasts.
  • Company holds $431M in cash through Q3 2028, expects $12M GSK milestone in Q4 2026; net loss widened to $61.9M from $53.9M year-over-year.
  • Q4 data expected for obesity drug WVE-007 (600mg dose) and alpha-1 antitrypsin candidate WVE-006, targeting single registrational trial path.
  • Stock rose 1.09% to $3.245 pre-market but trades near 52-week low of $3.04; analyst price targets range from $10-$42 suggesting upside potential.
  • CEO Bolno highlighted WVE-007's differentiation from GLP-1s via fat loss without muscle loss; GSK partnership validates oligonucleotide platform.
Last Updated: 28/10/2026, 12:52 am
Read Full Transcript

Earnings

Latest Release
27/10/2026
EPS / Forecast
-0.30 / -0.32
Revenue / Forecast
13.16M / 7.24M
EPS Revisions
Last 90 days

WVE Income Statement

Compare WVE to Peers and Sector

Metrics to compare
WVE
Peers
Sector
Relationship
P/E Ratio
−2.7x−7.2x−0.2x
PEG Ratio
0.06−0.140.00
Price/Book
1.4x2.1x2.6x
Price / LTM Sales
8.0x40.4x2.7x
Upside (Analyst Target)
-106.8%66.0%
Fair Value Upside
Unlock2.1%10.8%Unlock

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington’s disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
46.68M23.67%133.98M
Other Institutional Investors
173.68M76.33%498.45M
Public Companies & Retail Investors
0.000.00%0.00
Total
220.36M100.00%632.44M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
RA Capital Management, L.P.13.68%26,975,50577,420
RA Capital Healthcare Fund, L.P.13.68%26,975,50577,420

People Also Watch

14.19
NRIX
-3.67%
26.780
VKTX
-0.07%
42.91
PENG
-2.96%
8.520
CAPR
+2.65%

FAQ

What Is the Wave Life Sciences Ltd (WVE) Stock Price Today?

The Wave Life Sciences Ltd stock price today is 2.825 USD.

What Stock Exchange Does Wave Life Sciences Ltd Trade On?

Wave Life Sciences Ltd is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Wave Life Sciences Ltd?

The stock symbol for Wave Life Sciences Ltd is "WVE."

What Is the Wave Life Sciences Ltd Market Cap?

As of today, Wave Life Sciences Ltd market cap is 566.050M USD.

What Is Wave Life Sciences Ltd's Earnings Per Share (TTM)?

The Wave Life Sciences Ltd EPS (TTM) is -1.07.

From a Technical Analysis Perspective, Is WVE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Wave Life Sciences Ltd Stock Split?

Wave Life Sciences Ltd has split 0 times.

How Many Employees Does Wave Life Sciences Ltd Have?

Wave Life Sciences Ltd has 317 employees.

What is the current trading status of Wave Life Sciences Ltd (WVE)?

As of 17/11/2026, Wave Life Sciences Ltd (WVE) is trading at a price of 2.825 USD, with a previous close of 2.870 USD. The stock has fluctuated within a day range of 2.770 USD to 2.890 USD, while its 52-week range spans from 2.770 USD to 21.730 USD.

What Is Wave Life Sciences Ltd (WVE) Price Target According to Analysts?

The average 12-month price target for Wave Life Sciences Ltd is 16.632 USD, with a high estimate of 44 USD and a low estimate of 10 USD. 19 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +488.73% Upside potential.

What Is the WVE Premarket Price?

WVE's last pre-market stock price is 2.820 USD. The pre-market share volume is 12,690.000, and the stock has decreased by -0.050, or -1.740%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.